Skip to main content

Table 2 Differentially expressed microRNA among pooled reduction mammoplasty, histologically normal and ductal carcinoma in situa

From: Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer

 

HN versus PRM

DCIS versus PRM

DCIS versus HN

microRNA

Fold change

Pvalueb

Fold change

Pvalueb

Fold change

Pvalueb

let-7c [62]

15.23

3.46E-03c

0.31

1.25E-01

0.03

1.19E-03c

miR-7 [38]

3.12

1.35E-01

22.35

1.53E-03c

5.19

4.92E-02

miR-10b [13, 39]

2.90

1.59E-01

0.82

7.82E-01

0.04

2.58E-03c

miR-17-3p [32, 40]

19.04

2.14E-03c

2.20

2.85E-01

0.12

1.73E-02

miR-18a [34]

1.91

3.76E-01

20.88

1.76E-03c

3.53

1.12E-01

miR-21 [13, 31, 36, 40, 41]

6.74

2.23E-02

55.20

2.64E-04c

20.92

3.21E-03c

miR-93[34]

7.53

1.72E-02

193.86

3.33E-05d

160.47

1.59E-04d

miR-99a

1.90

3.79E-01

0.53

3.79E-01

0.02

9.19E-04c

miR-99b

3.08

1.39E-01

14.84

3.66E-03c

6.24

3.33E-02

miR-125b [13, 29]

0.93

9.24E-01

0.08

5.39E-03c

0.05

4.03E-03c

miR-127 [30, 31]

1.77

4.30E-01

0.25

7.81E-02

0.02

5.30E-04c

miR-130a

0.29

1.06E-01

0.01

1.38E-04d

0.09

1.01E-02

miR-145 [13, 14]

3.00

1.47E-01

0.80

7.52E-01

0.03

1.20E-03c

miR-181b [31, 40]

3.40

1.11E-01

14.90

3.64E-03c

5.46

4.42E-02

miR-182 [33]

2.00

3.45E-01

106.24

8.54E-05d

72.35

4.55E-04c

miR-183

2.52

2.15E-01

19.06

2.14E-03c

51.88

7.38E-04c

miR-191 [13]

6.75

2.23E-02

78.21

1.43E-04d

31.59

1.60E-03c

miR-193b [18]

2.20

2.84E-01

15.67

3.25E-03c

6.87

2.73E-02

miR-195 [35]

1.37

6.57E-01

0.06

2.78E-03c

0.13

2.15E-02

miR-200b [37]

1.70

4.63E-01

6.07

2.86E-02

51.31

7.50E-04c

miR-200c [37]

1.90

3.80E-01

26.41

1.08E-03c

19.98

3.48E-03c

miR-204 [13]

0.77

7.12E-01

0.04

1.32E-03c

0.08

8.12E-03c

miR-324-5p

2.86

1.64E-01

24.38

1.28E-03c

92.53

3.24E-04c

miR-365 [31]

4.05

7.45E-02

17.65

2.51E-03c

25.05

2.35E-03c

miR-376a

0.45

2.73E-01

0.06

3.14E-03c

0.24

7.91E-02c

miR-382

2.03

3.32E-01

0.11

1.20E-02c

0.06

4.71E-03c

miR-383 [34]

0.05

2.15E-03c

0.01

1.58E-04d

0.62

5.18E-01

miR-410

0.96

9.56E-01

0.15

2.33E-02c

0.00

1.11E-04d

miR-425-5p

1.38

6.57E-01

9.47

1.01E-02c

74.46

4.37E-04c

miR-449a

10.65

7.71E-03c

15.12

3.52E-03c

2.53

2.23E-01

miR-449b

0.79

7.37E-01

11.57

6.39E-03c

21.20

3.13E-03c

miR-486

0.02

2.06E-04d

0.01

9.73E-05d

0.34

1.65E-01

miR-489

0.06

2.73E-03c

0.10

8.61E-03c

0.25

8.62E-02

miR-511

0.40

2.20E-01

0.07

3.72E-03c

0.18

4.11E-02

miR-517c

0.07

3.48E-03c

0.01

1.29E-04d

0.36

1.82E-01

  1. aRM, reduction mammoplasty; PRM, pooled reduction mammoplasty; HN, histologically normal; DCIS, ductal carcinoma in situ; microRNA in boldface type have previously been implicated in invasive breast cancer; bP value determined by Student's t-test; cP < 1.7E-02 implies significance with a false-discovery rate of 0.05; dP < 2.5E-04 implies significance after the Bonferroni correction; fold change in expression between comparisons was considered significant if P < 5E-02.